News

Scientists publish research that reveals how the brain maintains attention on an object even while the eyes are making many rapid, voluntary movements.

A new discovery about the effects of aging in our cells could allow doctors to cure or prevent diabetes, fatty liver disease and other metabolic diseases – and possibly even turn back the clock on aging itself.

Scientists have developed a fast lab-based approach, creating positive co-dependent relationships between hosts and bacteria - termed ‘mutualisms’. These lab-developed bacterial relationships demonstrate how microbes can work with their hosts to prevent infection.

Researchers have shown that one olfactory receptor plays a critical role in the progression of prostate cancer. They found that activating an olfactory receptor called OR51E2 in prostate cancer cells caused the cancer to morph into the more aggressive form of the disease.

Researchers have identified a gene that provides insight into a key driver of prostate cancer — and a potential target for future therapy. The gene, ARLNC1, controls signals from the androgen receptor, a key player in prostate cancer.

MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.

Chemist Matthew D. Disney, PhD has developed a small-molecule-based tool that acts on RNA to selectively delete certain gene products. This deletion tool opens the possibility of creating drugs that can be taken conveniently as pills to correct genetic diseases.

The first human corneas have been 3D printed by scientists at Newcastle University. It means the technique could be used in the future to ensure an unlimited supply of corneas.

A hand-made super-microscope – capable of seeing the actual building blocks of a bacterial cell wall – has helped researchers decipher how bacteria are able to literally build a wall against the immune system, leading to often deadly disease.

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, researchers have shown that a new class of drugs is also effective against aggressive, hard-to-treat tumors such as lung and pancreatic cancers.